No profile data available.
Regen BioPharma, Inc. (RGBP) is a healthcare company in the additional cancer treatment drugs industry, based in La Mesa, United States.
It reported revenue of $236,561 for fiscal year 2025, about flat from fiscal year 2024, and net income of -$1.27 million. In Q2 2026 (the quarter ended March 31, 2026) revenue was $59,065, about flat from a year before. Its market capitalization was $167,527 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases.
Regen BioPharma reported $236,561 in revenue for fiscal year 2025, about flat from $236,560 in fiscal year 2024. In Q2 2026 revenue was $59,065.
$167,527 as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Curis, Inc. (CRIS), Marijuana Inc. (MAJI), Ocean Biomedical, Inc. (OCEA), Cnbx Pharmaceuticals Inc. (CNBX).